Field Kathryn, Lipton Lara
Department of Medical Oncology and Clinical Haematology, Western Hospital, Footscray 3011, Victoria, Australia.
World J Gastroenterol. 2007 Jul 28;13(28):3806-15. doi: 10.3748/wjg.v13.i28.3806.
The clinical management of metastatic (stage IV) colorectal cancer (CRC) is a common challenge faced by surgeons and physicians. The last decade has seen exciting developments in the management of CRC, with significant improvements in prognosis for patients diagnosed with stage IV disease. Treatment options have expanded from 5-fluorouracil alone to a range of pharmaceutical and interventional therapies, improving survival, and providing a cure in selected cases. Enhanced understanding of the biologic pathways most important in colorectal carcinogenesis has led to a new generation of drugs showing promise in advanced disease. It is hoped that in the near future the treatment paradigm of metastatic CRC will be analogous to that of a chronic illness, rather than a rapidly terminal condition. This overview discusses the epidemiology of advanced CRC and currently available therapeutic options including medical, surgical, ablative and novel modalities in the management of metastatic colorectal cancer.
转移性(IV期)结直肠癌(CRC)的临床管理是外科医生和内科医生共同面临的一项常见挑战。在过去十年中,CRC的管理取得了令人振奋的进展,IV期疾病患者的预后有了显著改善。治疗选择已从单纯的5-氟尿嘧啶扩展到一系列药物和介入治疗,提高了生存率,并在部分病例中实现了治愈。对结直肠癌发生过程中最重要的生物学途径的深入了解催生了新一代在晚期疾病中显示出前景的药物。人们希望在不久的将来,转移性CRC的治疗模式将类似于慢性病,而非快速致死性疾病。本综述讨论了晚期CRC的流行病学以及目前可用的治疗选择,包括转移性结直肠癌管理中的药物、手术、消融和新型治疗方式。